ADXN: Addex Therapeutics Ltd. Market Capitalization-to-Revenue Ratio
The rise in the Addex Therapeutics (ADXN) share price is driven by breakthroughs in Parkinson's disease therapy and patents. A reliable raw material supplier network ensures the continuity of testing. The company's average P/S reflects the business valuation trend, with the indicator currently standing at 56.40. The financial model relies on grants and payments from global pharma partners for the development of innovative small molecules.
Metric breakdowns and analytics for Addex Therapeutics, Ltd. (ADXN)
- stock quotes and analyst forecast:
- market capitalization information:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Addex Therapeutics|ADXN - Long-Term Debt to Equity|Current Liabilities to Equity Addex|ADXN - Company Aggregate Debts|Debts to Book Value Addex Therapeutics, Ltd.|ADXN - Company Long-Term Liabilities|Company Short-Term Debts Addex Therapeutics|Intermediate Liquidity Ratio addextherapeutics.com
- earnings and multiples data:
ADXN - Net Profit|Company Profit Forecast Addex Therapeutics|ADXN - P/E Multiple|Projected Price to Earnings Addex Therapeutics Ltd.|ADXN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Addex Therapeutics, Ltd.|ADXN - Operating profit EBITDA|Net earnings per share (EPS TTM) Addex Therapeutics|ADXN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months addextherapeutics.com|ADXN - Net earnings per share growth this year|Projected earnings per share growth rate for next year Addex Therapeutics
- total revenue and sales volume data:
General company analysis:ADXN - addextherapeutics.com
To build a high-quality portfolio, I utilize the P/S ratio, which determines the market value of a single dollar of revenue, allowing for an assessment of the business premium regardless of current profitability. In the case of Addex Therapeutics (ADXN), which focuses on R&D and the search for strategic partners, the P/S history reflects market expectations for the commercialization of allosteric modulators relative to actual sales volumes.
Who Addex Therapeutics competes with
Market Cap to Sales Volume BIIB|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|Price to Sales ACADIA Corp|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|vikingtherapeutics.com - Market Capitalization-to-Revenue Ratio|SUPN (Supernus) - P/S Multiple|P/S Multiple Catalyst Pharma|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY: Price-to-Sales Ratio|P/S Multiple BHVN (Biohaven Ltd.)|amylyx.com (AMLX) - Price to Sales|TRVI: Market Cap to Revenue|PRAX - P/S Multiple|AVXL (Anavex Corp) - Market Cap to Revenue|CBLL: Market Cap to Sales Volume|PRTA (Prothena Biosciences) - P/S Multiple|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|P/S Multiple ANNX|Market Cap to Revenue omeros.com OMER|Price-to-Revenue Ratio Neurogene Corp NGNE|Price-to-Revenue Coefficient AC Immune Inc (ACIU)|Voyager Therapeutics - P/S Multiple|NMRA - P/S Multiple|SCLX: P/S Multiple|Market Cap to Revenue Ratio TVGN|Market Cap to Revenue ACOG|Market Cap to Revenue Ratio CGTX (Cognition Therapeutics Inc.)|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|cassavasciences.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Price to Sales Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|cervomed.com (CRVO) - P/S Multiple|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Price to Sales|P/S Multiple RLMD (Relmada Therapeutics)|P/S Multiple annovisbio.com ANVS|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|Market Cap to Revenue Ratio NRSN|RVPH (Reviva Pharmaceuticals) - P/S Multiple|Price to Sales MetaVia, Inc. MTVA|Market Cap to Revenue NRXS (NeurAxis)|heliusmedical.com - Market Cap to Revenue Ratio|Passage Bio - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NEUP|NERV: Market Cap to Revenue|athira.com - Market Cap to Sales Volume|ALZN: P/S Multiple|Cyclerion Therapeutics, Inc. - Market Capitalization-to-Revenue Ratio|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Price to Sales Pasithea KTTA|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|P/S Multiple Cara Therapeutics Inc. CARA|CHRO - Price-to-Revenue Ratio|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales longboardpharma.com (LBPH)|Market Cap to Revenue MRNS|P/S Multiple NKGen Biotech Inc|Market Cap to Revenue NRBO (NeuroBo)|Market Cap to Sales Volume SAGE|P/S Multiple SNPX (Synaptogenix, Inc.)|Price-to-Revenue Coefficient trevena.com (TRVN)|Vigil Neuro - P/S Multiple|anewmeds.com (WENA) - Market Cap to Revenue|Cerevel (CERE) - Price-to-Revenue Ratio
